Brief: Vicore And Nippon Shinyaku Enter Into An Exclusive License Agreement
09/02/2024 07:20
Feb 9 (Reuters) - Vicore Pharma Holding AB (publ)
VICOR.ST :
* VICORE AND NIPPON SHINYAKU ENTER INTO AN EXCLUSIVE LICENSE
AGREEMENT TO DEVELOP AND COMMERCIALIZE C21 IN JAPAN
* UNDER TERMS OF AGREEMENT, VICORE WILL RECEIVE AN UPFRONT
PAYMENT
OF USD 10 MILLION AND IS ENTITLED TO POTENTIAL DEVELOPMENT AND
COMMERCIAL MILESTONE PAYMENTS UP TO A TOTAL OF USD 275 MILLION
Source text for Eikon: ID:nMFN20cCcw
Further company coverage: VICOR.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Nippon Shinyaku
See all newsTable: Nippon Shinyaku -Q1 group results (IFRS)
Brief: Elixirgen Therapeutics And Nippon Shinyaku Enter Into An Option Agreement For The Development And Commercialization Of Exg-7001 For Duchenne Muscular Dystrophy
Table: Nippon Shinyaku -2025/26 group results (IFRS)
Table: Nippon Shinyaku -2025/26 parent results
Table: Nippon Shinyaku -9-MTH group results (IFRS)